Revance Therapeutics (RVNC) Tops Q4 EPS by 9c

Revance Therapeutics (NASDAQ: RVNC) reported Q4 EPS of ($0.93), $0.09 better than the analyst estimate of ($1.02). Revenue for the quarter came in at $26 million versus the consensus estimate of $24.27 million.

For earnings history and earnings-related data on Revance Therapeutics (RVNC) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Bernstein SocGen on Meta Platforms Inc. (META): 'Risk-reward remains attractive'
• DA Davidson Reiterates Buy Rating on Box, Inc. (BOX) on Secular Tailwinds for Demand